齐拉西酮与氯氮平分别联合碳酸锂治疗躁狂症的疗效及安全性研究

Study on the Efficacy and Safety of Ziprasidone and Clozapine Combined with Lithium Carbonate Respectively in the Treatment of Mania

目的探讨齐拉西酮与氯氮平分别联合碳酸锂治疗躁狂症的疗效及安全性。方法选取昆明市精神病院2014年6月2015年6月收治的躁狂症患者62例，按照患者住院尾号的奇偶分成观察组和对照组各31例，观察组采用齐拉西酮联合碳酸锂治疗，对照组采用氯氮平联合碳酸锂治疗，比较两组的治疗效果和安全性。结果观察组总有效率为87．1％，对照组为83．9％，差异无统计学意义（P〉0．05）；观察组不良反应发生率为3．23％，低于对照组的19．35％，但差异无统计学意义（P〉0．05）。结论齐拉西酮联合碳酸锂治疗躁狂症的效果明显，且不良反应较少，安全性更高，值得临床推广使用。

Objective carbonate respectively in To investigate the efficacy and safety of ziprasidone and clozapine combined with lithium the treatment of mania. Methods Sixty-two patients with mania were selected from Kunming Mental Hospital from June 2014 to June 2015, and they were divided into observation group and control group with 31 cases in each group according to the parity of the tail number of patients＇ admission number. The observation group were treated with ziprasidone combined with lithium carbonate, while the control group were treated with clozapine combined with lithium carbonate. The therapeutic effect and safety of the two groups were compared. Results The total effective rate of the observation group was 87.1%, while that of the control group was 83.9%. The difference was not statistically significant （P 〉 0.05）. The incidence rate of adverse reaction of the observation group was 3.23%, which was lower than that of the control group （19.35%）. The difference was not statistically significant （P 〉 0.05）. Conclusion There is obvious effect on the treatment of mania with ziprasidone combined with lithium carbonate, and there is less adverse reactions and higher security. Ziprasidone combined with lithium carbonate in the treatment of mania is worthy of clinical promotion.